A phase 2b clinical study of GB-102, a potential twice-a-year treatment, is planned for the treatment of wet age-related macular degeneration, as well …



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *